Summary
Animals bearing the passable plasmacytoma MOPC 104E could be cured of palpable tumors (0.6–2.0×108 cells) with single 10–250 mg/kg doses of cyclophosphamide or single localized x-ray doses greater than 1600 R. Residual tumor immunity of cured animals was determined by their ability to reject graded numbers of viable MOPC 104E cells 30 days following curative therapy. High doses of cyclophosphamide (250 mg/kg), although curative, left significantly less residual tumor immunity than either low dose cyclophosphamide (10 mg/kg) or localized irradiation. Animals cured of palpable tumors by high doses of cyclophosphamide nonetheless rejected greater numbers of cells in secondary challenge than did untreated control animals.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Bach, J. F.: The mode of action of immunosuppressive agents, p. 312. New York: North Holland/American Elsevier Co. 1975
Einstein, A. B., Fass, L., Fefer, A.: Suppression of secondary immunity to a tumor allograft by cyclophosphamide and BCNU. Cancer Res. 25, 492 (1975)
Heberman, R. B., Aoki, T.: Immune and natural antibodies to syngeneic murine plasma cell tumors. J. Exptl. Med. 136, 94 (1972)
Hill, D. L.: A review of cyclophosphamide. Springfield, Ill.: Charles C. Thomas 1975
Hiramoto, R., Ghanta, V. K.: Quantitation of total body tumor cell (MOPC 104E). I. Subcutaneous model. J. Nat. Cancer Inst. 52, 1199 (1974a)
Hiramoto, R. N., Ghanta, V. K., Hamilin, N. H.: Quantitation of total body tumor cells (MOPC 104E). II. Ascites tumor model. J. Nat. Cancer Inst. 53, 767 (1974b)
Hiramoto, R., Ghanta, V., Durant, J. R.: Evaluation of a cooperative group human myeloma protocol using the MOPC 104E myeloma model. Cancer Res. 35, 1309 (1975)
Kiessling, R., Klein, E., Wigzell, H.: “Natural” killer cells in the mouse. I. Cytotoxic cells with specificity for moloney leukemia cells. Specificity and distribution according to genotype. Eur. J. Immunol. 5, 112 (1975)
Litchfield, J. T., Wilcoxon, F.: A simplified method of evaluating dose-effect experiments. J. Pharmacol. Exp. Therap. 96, 99 (1949)
Martinez, D., Lakasewycz, O. A. L., Murphy, W.: Immune mechanisms in leukaemia. Suppression of cellular immunity by drugs and x-irradiation. J. Immunol. 115, 724 (1976)
McCoy, J. L., Dean, J. H., Law, L. W., Williams, J., McCoy, N. T., Holiman, B. T.: Immunogenicity, antigenicity, and mechanisms of tumor rejection in mineral oil induced plasmacytomas. Int. J. Cancer 14, 264 (1974)
Rouse, B. T., Röllinghoff, M., Warner, N. L.: Tumor immunity to murine plasma cell tumors. II. Essential role of T lymphocytes in immune response. Eur. J. Immunol. 3, 218 (1973)
Schlossberg, M., Hollander, V. P.: Imuran induced regression of plasma cell tumor MOPC-315. Cancer Res. 33, 1953 (1973)
Stewart, C. C., Perez, C. A.: Effect of irradiation on immune responses. Radiology 118, 201 (1976)
Ting, C. C., Rodrigues, D., Bushar, G. S., Herberman, R. B.: Cell-mediated immunity to Friend virus induced leukemia. II. Characteristics of primary cell-mediated cytotoxic response. J. Immunol. 116, 236–243 (1976)
Author information
Authors and Affiliations
Additional information
This investigation received support from NIH Grants 13371, 17065, 05136, and 09082 from the National Cancer Institute
Submitted in partial fulfilment of the degree Doctor of Philosophy in Radiation Biology
Rights and permissions
About this article
Cite this article
Lubet, R.A., Carlson, D.E. Tumor immunity directed against MOPC 104E: Effect of various therapeutic regimens. Cancer Immunol Immunother 2, 267–270 (1977). https://doi.org/10.1007/BF00206008
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00206008